Sunshine Biopharma Inc. will see Dr. Andrew Keller leave its board after his current term ends at the next annual Shareholder meeting, as he will not seek or accept reelection. Investors have a defined governance transition to monitor at that meeting, with the announcement identifying no other Leadership change.

Key Highlights

  • Dr. Andrew Keller notified Sunshine Biopharma on August 25, 2026, that he would not pursue another board term.
  • Keller’s current director term ends when the next annual shareholder meeting is completed.
  • Chief Executive Officer Dr. Steve N. Slilaty signed the company’s dated August 28, 2026, report.

Keller’s Current Board Position

Dr. Andrew Keller currently serves as a director of Sunshine Biopharma Inc. The article identifies him as holding an active board position while describing the point at which his present term will conclude.

Keller’s decision applies to the completion of that present term. The article therefore frames the development around the end of the existing term rather than providing a separate immediate departure date.

Timing of the Term’s Completion

Keller’s present term expires at the next annual meeting of shareholders.

The timing described for Keller’s departure is tied to the next annual meeting. This makes the meeting the relevant event for understanding when his present board term expires.

Separation From the Report Date

Keller’s notice separates the timing of his departure from the date of the company’s report. The article expressly distinguishes the term-ending event from the date on which Sunshine Biopharma’s report was signed.

The report date is August 28, 2026. That date identifies when the company’s report was signed, while Keller’s notice identifies the next annual meeting as the point connected to completion of his present term.

Sunshine Biopharma’s Report

Sunshine Biopharma’s report addresses the board-term information concerning Keller. It states the relevant relationship between his current directorship, his present term, and the next annual meeting of shareholders.

The document is presented on behalf of Sunshine Biopharma Inc.

Report Signatory

Dr. Steve N. Slilaty signed the company’s report. He is identified as Sunshine Biopharma’s chief executive officer in the article.

The report was signed on Sunshine Biopharma’s behalf by Slilaty. His signature establishes who executed the document, while the article separately identifies Keller’s board-term timing.

Cited Law

The report cites the Securities Exchange Act of 1934. This citation appears in the document described by the article and forms part of the report’s stated legal reference. Its central points remain Keller’s current directorship, completion of his present term at the next annual meeting, and Slilaty’s signing of the report on August 28, 2026.